Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | Del...
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
The shift from conventional systemic treatments to high-efficacy biologics and targeted oral agents has significantly expanded market value. Additionally, the launch of emerging therapies such as zasocitinib (Takeda/Nimbus Therapeutics), icotrokinra (JNJ-77242113 [Johnson & Johnson Innovative Medicine and Protagonist Therapeutics]), piclidenoson (CF101 [Can-Fite BioPharma]), ESK-001 (Alumis), SFA-002 (SFA Therapeutics), and others further boost the market. LAS VEGAS Jan. 7, 2026 /PRNewswire/ -- DelveInsight's Psoriasis Market Insights report includes a comprehensive understanding of current treatment practices, psoriasis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Psoriasis Market Summary The market size for psoriasis was found to be USD 33.4 billion in the leading markets [the United S
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
PTGX
Earnings
- 11/6/25 - Miss
PTGX
Sec Filings
- 1/13/26 - Form 4
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- PTGX's page on the SEC website